MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
1.600
-0.130
-7.51%
After Hours: 1.600 0 0.00% 19:34 08/14 EDT
OPEN
1.690
PREV CLOSE
1.730
HIGH
1.710
LOW
1.580
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
0.8302
MARKET CAP
296.45M
P/E (TTM)
-1.2060
1D
5D
1M
3M
1Y
5Y
1D
Neumora Therapeutics, Inc. (NMRA) Receives a Rating Update from a Top Analyst
TipRanks · 17h ago
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)
TipRanks · 17h ago
Neumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO
NASDAQ · 20h ago
Neumora Therapeutics Announces CEO Transition and Q2 Results
TipRanks · 22h ago
Neumora Therapeutics Promotes Pinto to CEO
Dow Jones · 22h ago
Neumora Therapeutics GAAP EPS of -$0.23 beats by $0.01
Seeking Alpha · 23h ago
*Neumora Therapeutics: Co-founder Paul L. Berns Will Serve as Executive Chair
Dow Jones · 23h ago
*Neumora Therapeutics Names Joshua Pinto Pres and CEO
Dow Jones · 23h ago
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.